Unlike cannabis, which remains federally illegal in the U.S., the work psychedelic companies are doing is legal. The Canadian Securities Exchange, which has become the go-to bourse for U.S. cannabis companies that can’t list in their home country, is also expecting listings from psychedelic drug companies in 2020. The first companies developing medical treatments from psychedelic drugs like LSD, ketamine and the active ingredient in magic mushrooms are gearing up to list on Canadian stock exchanges. This has created a legal way for these companies to conduct research on otherwise illegal drugs, opening the door to public listings. Field Trip is considering a public listing, although Levy also sees further opportunities to raise private funding, he said.
The first companies developing medical treatments from psychedelic drugs like LSD, ketamine and the active ingredient in magic mushrooms are gearing up to list on Canadian stock exchanges.
Washington, DC sets stage for decriminalizing psychedelics Psychedelics associated with reduction in problematic drug use: study Kevin...Read the full article @ The Growth Op